Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers c
9 min read
ICP-B381 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
ICP-B381: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII(University of Manchester) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII(University of Manchester): Phase 1/2. 2026 diligence verdict: HOLD / OPTION.
9 min read
BRT-OpCT-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
BRT-OpCT-001: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive HPCs(NCI) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive HPCs(NCI): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers
9 min read
Oncolytic measles virus encoding thyroidal sodium iodide symporter infected mesenchymal stem cells(Mayo Clinic) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Oncolytic measles virus encoding thyroidal sodium iodide symporter infected mesenchymal stem cells(Mayo Clinic): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidenc
9 min read
Recombinant Human Follicle Stimulating Hormone Fc Fusion Protein(Guangzhou Unicohealth Biological Technology Co Ltd) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Recombinant Human Follicle Stimulating Hormone Fc Fusion Protein(Guangzhou Unicohealth Biological Technology Co Ltd): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Ev
9 min read
Personalized Synthetic Long Peptide Vaccine(Jaime Leandro Foundation for Therapeutic Cancer Vaccines) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Personalized Synthetic Long Peptide Vaccine(Jaime Leandro Foundation for Therapeutic Cancer Vaccines): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review c
9 min read
HepaCure Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
HepaCure: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Umbilical Cord-Derived Mesenchymal Stem Cell(Vinmec Research Institute of Stem Cell and Gene Technology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Umbilical Cord-Derived Mesenchymal Stem Cell(Vinmec Research Institute of Stem Cell and Gene Technology): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence revie
9 min read
Autologous CD34+ cell enriched population containing HSPCs transduced ex vivo using a LVV encoding the hPD-L1 DNA Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Autologous CD34+ cell enriched population containing HSPCs transduced ex vivo using a LVV encoding the hPD-L1 DNA: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evide
9 min read
CD40L-augmented Tumor Infiltrating Lymphocytes( H. Lee Moffitt Cancer Center & Research Institute, Inc.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
CD40L-augmented Tumor Infiltrating Lymphocytes( H. Lee Moffitt Cancer Center & Research Institute, Inc.): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence revie